Xueyuan Zhou

Xueyuan Zhou has worked in the field of Immuno-Oncology since 2011. In 2011, they began as a Postdoctoral Fellow at Leidos Biomedical Research Inc. (SAIC-Frederick Inc.), where they developed T cell receptor sequencing method on Illumina MiSeq platform and evaluated flow cytometry method to simultaneously detect HIV RNA and proteins in single cell. In 2016, they became a Scientist at Intrexon Corporation, where they led the project to develop bi-specific trapping proteins and developed in vitro immuno-oncology analytical methods to test their therapeutical effect. xueyuan was also the biology leader of ROR1 chimeric antigen receptor (CAR)-T project. In 2018, they joined EMD Serono, Inc. as a Senior Scientist, Immuno-Oncology, where they led and drove in vitro immuno-oncology activity to investigate anti-tumor effects of CD3xROR1 bispecific T-cell-engager and CD137xTAA bispecific antibody projects. In the same year, they also joined Bicycle Therapeutics as a Scientist, Immuno-Oncology, where they led design and development of in vitro and in vivo immuno-oncology analytical methods to investigate anti-tumor effects of CD137xNectin4 (BT7480) and CD137xEphA2 (BT7455) bispecific peptide drugs. Currently, they are the Associate Director, Head of In-vitro Pharmacology/Immuno-Oncology at Fuse Biotherapeutics, where they lead and drives in vitro immuno-oncology activity to investigate anti-tumor effects of multi-specific antibody projects, designs and develops immuno-oncology/immunology analytical methods to investigate and screen anti-tumor function, toxicity, PK/PD, PD biomarkers for multi-specific antibodies, and supports CSO and CBO in building immuno-oncology pipeline, laboratory and team to support the ongoing projects.

Xueyuan Zhou completed a B.S. in Applied Physics (Bioiphysics) from Nankai University between 1999 and 2003. xueyuan then completed an M.S. in Biophysics (Immunology) from Nankai University between 2003 and 2006. Finally, they completed a Ph.D. in Biochemistry (Immunology) from Brigham Young University between 2006 and 2011.